Author Archives: Lindsey Shapiro PhD

Rituximab treatment led to rates of remission and relapse prevention in Mexican patients with ANCA-associated vasculitis (AAV) that were similar to those previously observed in other patient populations, a real-world study found. It was also associated with a higher rate of infections, the study found. Overall, about 65% of…

People with rheumatoid arthritis (RA) who also have ANCA-associated vasculitis (AAV) are more likely to develop signs of kidney impairment than those without AAV, a small study showed. Among patients with both disorders, AAV was usually diagnosed after RA, and often was asymptomatic, highlighting that an early RA diagnosis…

Prolonged low levels of immunoglobulin antibodies as a result of rituximab treatment did not increase the likelihood of serious infections in children with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) — the two most common forms of ANCA-associated vasculitis (AAV). This was according to a post-hoc analysis of…

Infliximab successfully led to the remission of respiratory symptoms in a 15-year-old boy with steroid-resistant granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis (AAV), according to a case report. More studies are needed to determine the treatment’s safety profile in children, the researchers noted. The report, “…

Antimicrobial webs produced by neutrophils — immune cells that respond quickly to bodily injury — may be implicated in the development of ANCA-associated vasculitis (AAV) accompanied by lung scarring (fibrosis), a recent review of several published studies revealed. These webs of DNA and antimicrobial proteins are known as neutrophil…

Genetic biomarkers and immune pathways related to kidney damage in people with ANCA-associated vasculitis (AAV) were identified in a recent study. The five identified biomarker genes may be involved in the progression of kidney damage through immune system signaling, its researchers said. The study, “Identification of Hub Biomarkers and…

People with ANCA-associated vasculitis (AAV) want more disease-related information from their healthcare providers for better self-management, a study based on patient interviews reported. Patients said they needed better communication about symptoms, relapses, living with AAV, and mental health. This led researchers to call on healthcare professionals to…

A case of reinfection with COVID-19 has been reported in a patient who received immunosuppressive treatment for ANCA-associated vasculitis (AAV), which was linked to her first infection. Before her second infection, the 70-year-old African woman was given prednisolone and cyclophosphamide to combat AAV-associated kidney damage that had occurred after her…

A third COVID-19 vaccine dose boosts immune responses against the SARS-CoV-2 virus in people with ANCA-associated vasculitis (AAV), researchers in Germany report. Antibodies against the virus and the ability to fight off more highly transmissible variants like delta dip over time after the second dose. But…

The European Commission has approved Tavneos (avacopan) as an add-on therapy for adults with severe granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) — the two main types of ANCA-associated vasculitis (AAV). Following the expected launch this year, Tavneos will be the first available oral therapy for…